Your browser doesn't support javascript.
loading
Prevalencia de enfermedad arterial periférica con la determinación del índice tobillo-brazo en pacientes con artritis reumatoide / Prevalence of peripheral arterial disease measured with the ankle-arm index in rheumatic patients suffering from rheumatoid arthritis
Da Silva C, Johana M; Constantino Chahin, Ramez; Gómez, Mayela; Salazar, Lesbia.
  • Da Silva C, Johana M; Instituto Venezolano de los Seguros Sociales. Hospital Universitario Ángel Larralde. Valencia. VE
  • Constantino Chahin, Ramez; Instituto Venezolano de los Seguros Sociales. Hospital Universitario Ángel Larralde. Valencia. VE
  • Gómez, Mayela; Instituto Venezolano de los Seguros Sociales. Hospital Universitario Ángel Larralde. Valencia. VE
  • Salazar, Lesbia; Instituto Venezolano de los Seguros Sociales. Hospital Universitario Ángel Larralde. Valencia. VE
Med. interna (Caracas) ; 33(2): 95-103, 2017. tab
Article in Spanish | LILACS, LIVECS | ID: biblio-1009168
RESUMEN
La enfermedad arterial periférica (EAP) afecta 15-20% de las personas mayores de 70 años.

Objetivo:

Establecer la prevalencia de enfermedad arterial periférica mediante la determinación del índice tobillo brazo (ITB) en pacientes con Artritis Reumatoide que acuden a la consulta de reumatología, en el Hospital Universitario "Ángel Larralde" Valencia-Venezuela durante el periodo Enero-Abril 2016.

Métodos:

Estudio descriptivo, transversal y de campo. Se estudiaron 50 pacientes. La recolección de los datos personales y familiares, así como el registro de las medidas antropométricas, se hizo mediante un formulario prediseñado, utilizando una entrevista estructurada.

Resultados:

El promedio de edad fue de 54,6 ± 11 años, con un rango de 50 a 60 años; predominio del sexo femenino 76%; índice isquémico promedio de 0,74 ± 0,38 siendo normal en 20%, 42% con EAP leve a moderada, 28% con EAP grave y 10% vaso no compresible; la edad sigue siendo el marcador principal de riesgo de EAP. Entre los factores de riesgo cardiovascular (FRCV) modificables la dislipidemia se observó en 38%,obesidad 12%, sedentarismo 100%, consumo de alcohol 2%, tabaquismo 32%, hipertensión arterial 32% y Diabetes Mellitus (DM) 22%. El 74% de los pacientes han utilizado terapia biológica como tratamiento para Artritis Reumatoide dada por Adalimumab/Leflunomida 24%, Metrotrexate/ Etarnecept 10%, Metrotrexate /Adalimumab 8%. Al correlacionar los FRCV no modificables (edad, sexo) y modificables (dislipidemia, obesidad, sedentarismo, consumo de alcohol, tabaquismo, antecedentes de HTA y DM) con el uso de la terapia biológica sólo se observó relación estadísticamente significativa con el tabaquismo (P=0.04) y, con una relación inversa muy baja (-0.293) pero estadísticamente significativa (P=0.039), con el valor bioquímico de la glicemia.

Conclusiones:

En vista de la poca asociación entre la alteración del ITB con los factores de riesgo cardiovascular, podría plantearse la posibilidad que la Artritis Reumatoide per se sea un factor independiente para desarrollar EAP(AU)
ABSTRACT
Peripheral arterial disease (PAD) affects 15-20% of people older than 70 years.

Objectives:

to determine the prevalence of peripheral arterial disease measuring the ankle-brachial index in ambulatory patients who had Rheumatoid Arthritis, at the Hospital Universitario Angel Larralde in Valencia-Venezuela during the period 2015-2016.

Methods:

This is a descriptive, transversal study, with a sample of 50 patients who attended the rheumatology clinic of the hospital. The collection of personal and family data as well as the registration of anthropometric measurements were done through a pre-designed form with a structured interview. The average age was 54.6 ± 11 years.

Results:

gender 76% were female; the average age was between 50 and 60 years, mean 0.74 ± 0.38; the Ischemic index was normal in 20%, 42% had mild to moderate PAD, in 28% it was severe and 10% non compressible. Age remains as the main risk marker for EAP; among the modifiable risk factors, dyslipidemia was observed in 38%, obesity 12%, sedentarism 100%, alcohol consumption 2%, smoking 32%, hypertension 32% and Diabetes Mellitus 22%. 74% of patients had received biological therapy as a treatment for rheumatoid arthritis Adalimumab / Leflunomide 24%, Metrotrexate / Etarnecept 10%, Metrotrexate / Adalimumab 8%. When correlating non-modifiable CVD (age, sex) and modifiable (dyslipidemia, obesity, sedentary lifestyle, alcohol consumption, smoking, history of hypertension and DM) and use of biological therapy, a statistically significant relationship with smoking (P=0.04), and with a very low inverse (-0.293) statistically significant (P = 0.039) with the biochemical value of glycemia.

Conclusions:

Rheumatoid Arthritis per se may be an independent factor in the development of PAD. Recommendation there is a need to routinely perform ABI in patients with asymptomatic RA from a cardiovascular point of view.(AU)
Subject(s)

Full text: Available Index: LILACS (Americas) Main subject: Ankle Brachial Index / Peripheral Arterial Disease / Obesity Type of study: Practice guideline / Health technology assessment / Observational study / Prevalence study / Qualitative research / Risk factors / Screening study Limits: Female / Humans / Male Language: Spanish Journal: Med. interna (Caracas) Journal subject: Glƒndulas End¢crinas / Horm“nios / Internal Medicine Year: 2017 Type: Article Affiliation country: Venezuela Institution/Affiliation country: Instituto Venezolano de los Seguros Sociales/VE

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Ankle Brachial Index / Peripheral Arterial Disease / Obesity Type of study: Practice guideline / Health technology assessment / Observational study / Prevalence study / Qualitative research / Risk factors / Screening study Limits: Female / Humans / Male Language: Spanish Journal: Med. interna (Caracas) Journal subject: Glƒndulas End¢crinas / Horm“nios / Internal Medicine Year: 2017 Type: Article Affiliation country: Venezuela Institution/Affiliation country: Instituto Venezolano de los Seguros Sociales/VE